Glucommander is an FDA-cleared software system that calculates insulin doses for hospitalized patients in real time. Developed by Glytec, it uses algorithms to analyze a patient’s blood sugar readings and insulin sensitivity, then recommends precise dosing adjustments so healthcare teams don’t have to rely on manual calculations. It’s approved for use in patients two years and older receiving either intravenous (IV) or injection-based insulin therapy.
How Glucommander Works
At its core, Glucommander is a computer-guided decision tool. A nurse enters a patient’s blood sugar reading into the system, and its algorithms calculate two things: how much insulin to give right now, and when to check the patient’s blood sugar again. Each time a new reading comes in, the system recalibrates. It tracks how the patient has responded to previous doses and uses that history to predict future insulin needs, essentially learning each patient’s unique sensitivity to insulin over time.
This continuous recalibration is what sets it apart from static insulin protocols, where a doctor writes an order like “give X units if blood sugar is above Y.” Those fixed sliding-scale orders don’t adapt. Glucommander does, adjusting its recommendations as a patient’s condition changes throughout a hospital stay.
IV and Injection-Based Modules
The system handles two distinct clinical scenarios. The IV module manages patients who receive insulin through a continuous drip, common in critical care settings like ICUs where blood sugar can spike dangerously after surgery, during sepsis, or in diabetic emergencies. The injection-based (subcutaneous) module covers patients on standard insulin shots, typically on general hospital floors.
Glucommander also includes a specific module for transitioning patients from IV insulin to injections. This is a particularly risky moment in hospital care. The standard protocol calls for starting injection-based insulin about two hours before stopping the IV drip, because there’s a gap before injected insulin takes effect. If that overlap doesn’t happen, blood sugar can rise rapidly. The transition module helps coordinate this timing so the handoff doesn’t create a dangerous gap in coverage.
Impact on Blood Sugar Control
Uncontrolled blood sugar in hospitalized patients is a serious and common problem. It slows wound healing, increases infection risk, and extends hospital stays. Glucommander’s primary value is tightening that control with fewer episodes of dangerously low blood sugar (hypoglycemia).
In a comparison published in The American Journal of Managed Care, the share of patients experiencing hypoglycemia (blood sugar dropping below 70 mg/dL) was 20.1% with Glucommander, compared to 30.3% with usual care. That improvement came despite the system requiring 69,256 fewer individual insulin adjustments across the patient population studied. In other words, it achieved better outcomes with less manual intervention.
Time and Cost Savings for Hospitals
Because the system automates dosing calculations, it significantly reduces the time nurses spend on insulin management. Data from Glytec shows the system saves roughly 200 minutes per patient over the course of their stay, which translates to about 30 minutes saved per nursing shift. For a busy ICU nurse managing multiple patients on insulin drips, that recovered time is substantial.
The financial case is also significant. At one 610-bed regional medical center, implementing Glucommander produced $9.7 million in savings during the first year. Much of that likely ties back to a reported 3.2-day reduction in average length of stay for patients managed with the system. Shorter stays mean fewer hospital-acquired complications, less resource use, and faster bed turnover.
Where It’s Used
Glucommander is designed primarily for hospitals and health systems, though facilities can implement it in outpatient settings as well. It’s most commonly found in ICUs, surgical units, and medical floors where patients need active blood sugar management. The system sits within a broader platform called the Glytec eGlycemic Management System (eGMS), which may include additional tools for glycemic surveillance and reporting across a hospital.
FDA Clearance
Glucommander received FDA clearance through the 510(k) pathway, the process used for medical devices that are substantially equivalent to something already on the market. Glytec submitted its application in August 2015, and the FDA granted clearance in August 2017 under regulation number 868.1890. This regulatory classification means the system is recognized as a clinical decision support tool, not just a wellness app or informational product.
What Glucommander Doesn’t Do
It’s important to understand that Glucommander recommends doses but does not administer them. A nurse or provider still reviews each recommendation and decides whether to follow it. The system also doesn’t replace the need for frequent blood sugar monitoring. It depends on regular manual readings entered into the system to function accurately. If readings are delayed or skipped, the algorithm can’t adapt properly, and gaps in care can still occur.
Glucommander is also not a tool for managing diabetes at home. It’s built for the hospital environment, where patients are monitored continuously and insulin needs can change hour to hour based on medications, procedures, nutrition, and stress responses that don’t apply in outpatient life.